Liraglutide for type 2 diabetes?
Drug Ther Bull 48(5):50-3 (2010) PMID 20447980
Several drugs that act on the incretin hormonal system are now licensed in the UK as add-on therapy for patients with type 2 diabetes mellitus and inadequate glycaemic control. Liraglutide (Victoza--Novo Nordisk) is a recently licensed long-acting glucagon-like peptide-1 (GLP-1) mimetic that can be given once daily as a subcutaneous injection, as part of either dual or triple therapy. Advertising claims that use of the drug leads to reductions in weight; reductions in systolic blood pressure; and improvements in beta-cell function, as well as reductions in blood glucose concentrations. Here we assess the evidence for these claims and consider whether liraglutide has a role in the management of patients with type 2 diabetes.
DOI: 10.1136/dtb.2010.01.0006
Version: za2963e q8zaa q8zb4 q8zce q8zde q8ze4 q8zf6 q8zgf